| Revenue growth | $643.7M, +3.1% YoY in FY26. |
|---|---|
| Margins | EBITDA 16.0% (+50bps); Gross Margin 31.9% (+220bps). |
| Order book | $912.7M, up 17.8% YoY. |
| Demand visibility | Strong $912.7M order book; 36% AI-influenced. |
| Management confidence | High focus on AI-Native organization by design. |
Growth
Revenue grew 3.1% YoY to $643.7M; Net Profit reached $87M (13.5% margin); Order book rose 17.8% to $912.7M.
Outlook
FY27 focus on AI-Native transformation, large deal execution, and verticalization. Dividend increased to ₹15/share (~44% payout).
Risks
Macro headwinds: US immigration tightening, client budget cuts, and Nifty IT index decline impacting sentiment.
Earnings Call filed with NSE, NSE: ZENSARTECH. Summary written with AI assistance from the document.
Zensar Technologies Ltd: key numbers
- Share price
- ₹440.60
- Market cap
- ₹10,027 Cr
- Revenue (annual)
- ₹5,687 Cr
- Net profit (annual)
- ₹774.6 Cr
- P/E (TTM)
- 12.9×Sector 21.8×
- Promoter holding
- 48.99%-0.01% QoQ
- FII holding
- 10.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zensar Technologies Ltd
All →Zensar Technologies Credit Rating
ICRA Limited has reaffirmed the credit rating of Zensar Technologies for its long-term and short-term fund/non-fund based bank facilities, totaling ₹191 Crore.
- Value
- ₹191.0 Cr
Zensar Technologies Employee Stock Options
Designated person Vijayasimha Alilughatta acquired 8,983 shares of Zensar Technologies through an ESOP exercise. The transaction is valued at ₹0.43 Crore.
- Value
- ₹0.43 Cr
Zensar Technologies Employee Stock Options
Zensar Technologies has allotted 25,691 equity shares to employees following the exercise of their vested ESOPs.
Zensar Technologies Other Announcement
Zensar Technologies Ltd has filed its quarterly shareholding pattern for the period ended December 31, 2025, in compliance with regulatory requirements.
Zensar Technologies Merger & Restructuring
Zensar Technologies announced the completed merger of its US subsidiaries M3BI LLC and Bridgeview Life Sciences LLC into Zensar Technologies Inc. The mergers become effective September 1, 2026.
- Execution
- Effective September 1, 2026
Zensar Technologies Other Announcement
Zensar Technologies Limited has received an independent ESG score of 74 from Crisil ESG Ratings & Analytics Limited, categorizing the company under 'Leadership' for FY2026.